Compare CVS Health Corp (CVS) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Huntington Ingalls Industries Inc — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while Huntington Ingalls Industries Inc trades at $280 (market cap $11.03B). The key difference: CVS Health Corp is far larger — about 12.3× Huntington Ingalls Industries Inc's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | HII | |
|---|---|---|
Market Cap | $135.48B | $11.03B |
Sector | Health | Technology |
52-Week High | $106.18 | $453.73 |
52-Week Low | $58.75 | $252.93 |
Enterprise Value | $202.02B | $13.75B |
Dividend Yield | 2.51% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
HII trades at $284.86, down 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows stable fundamentals with a P/E of 18.19 and net income margin of 4.71%, supported by recent earnings beats. Recent news highlights contract awards and leadership additions, reinforcing its defense sector presence.
The outlook is cautiously optimistic with a consensus price target of $354.50, implying significant upside. Risks include execution on new contracts and defense budget dependencies, but analyst sentiment leans positive with 44% buy ratings. The upcoming Q2 2026 earnings report on July 30 will be a key catalyst for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
